← Back to Clinical Trials
Recruiting NCT05392881
NCT05392881 Interstitial Lung Disease Research Unit Biobank
◆ AI Clinical Summary
Plain-language summary for patients
| NCT ID | NCT05392881 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Kansas Medical Center |
| Condition | Interstitial Lung Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2021-08-09 |
| Primary Completion | 2031-08-01 |
Trial Parameters
Condition Interstitial Lung Disease
Sponsor University of Kansas Medical Center
Study Type OBSERVATIONAL
Phase N/A
Enrollment 1,000
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2021-08-09
Completion 2031-08-01
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.
Eligibility Criteria
Inclusion Criteria: 1. The participant is a patient at TUKHS or has agreed to participate in a study approved by the KUMC Human Research Protection Program (HRPP) 2. The participant is being followed for the presence of autoimmune disease, ILD or other rare lung diseases at TUKHS. 3. The participant is ≥ 18 years of age. 4. The participant has signed an approved consent for this study (living patients only)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology